These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 15173837)

  • 1. GSK3 inhibitors: development and therapeutic potential.
    Cohen P; Goedert M
    Nat Rev Drug Discov; 2004 Jun; 3(6):479-87. PubMed ID: 15173837
    [No Abstract]   [Full Text] [Related]  

  • 2. MEN-10755. Menarini.
    Jones K
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1473-8. PubMed ID: 14763135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMT-3. CollaGenex.
    Fingleton B
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1460-7. PubMed ID: 14763133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug treatment for chronic obstructive pulmonary disease.
    Wark P
    IDrugs; 2003 Sep; 6(9):874-9. PubMed ID: 12964067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycogen synthase kinase 3: a drug target for CNS therapies.
    Bhat RV; Budd Haeberlein SL; Avila J
    J Neurochem; 2004 Jun; 89(6):1313-7. PubMed ID: 15189333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
    Liu SN; Shen ZF
    Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of potential glycogen kinase-3 inhibitors by structure based virtual screening.
    Dessalew N; Bharatam PV
    Biophys Chem; 2007 Jul; 128(2-3):165-75. PubMed ID: 17482749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor tyrosine kinase inhibitors as anti-angiogenic agents.
    Kim DW; Lu B; Hallahan DE
    Curr Opin Investig Drugs; 2004 Jun; 5(6):597-604. PubMed ID: 15242247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib ditosylate GlaxoSmithKline.
    Kim TE; Murren JR
    IDrugs; 2003 Sep; 6(9):886-93. PubMed ID: 12964069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 109881 Aventis.
    Ojima I; Geney R
    Curr Opin Investig Drugs; 2003 Jun; 4(6):737-40. PubMed ID: 12901234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GSK3 inhibitors and disease.
    Hernández F; Nido JD; Avila J; Villanueva N
    Mini Rev Med Chem; 2009 Aug; 9(9):1024-9. PubMed ID: 19689399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nemifitide. Innapharma.
    Dingemanse J
    Curr Opin Investig Drugs; 2003 Jul; 4(7):859-62. PubMed ID: 14619408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. M-40403 Metaphore Pharmaceuticals.
    Di Napoli M; Papa F
    IDrugs; 2005 Jan; 8(1):67-76. PubMed ID: 15650944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in glycogen phosphorylase inhibitor design.
    Oikonomakos NG; Somsák L
    Curr Opin Investig Drugs; 2008 Apr; 9(4):379-95. PubMed ID: 18393105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ganstigmine. Chiesi.
    Johnson A
    Curr Opin Investig Drugs; 2003 Jul; 4(7):868-73. PubMed ID: 14619410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lerisetron. FAES.
    Huckle R
    Curr Opin Investig Drugs; 2003 Jul; 4(7):874-7. PubMed ID: 14619411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CKD-602. Chong Kun Dang.
    Crul M
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1455-9. PubMed ID: 14763132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening.
    Dessalew N; Bharatam PV
    Chem Biol Drug Des; 2006 Sep; 68(3):154-65. PubMed ID: 17062013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds.
    Werstuck GH; Kim AJ; Brenstrum T; Ohnmacht SA; Panna E; Capretta A
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5465-7. PubMed ID: 15482904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.
    Tavares FX; Boucheron JA; Dickerson SH; Griffin RJ; Preugschat F; Thomson SA; Wang TY; Zhou HQ
    J Med Chem; 2004 Sep; 47(19):4716-30. PubMed ID: 15341487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.